CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release dated September 24, 2021 titled 'Zydus Cadila receives final approval from USFDA for Apremilast Tablets."24-09-2021
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release dated September 24, 2021 titled 'Zydus Cadila receives final approval from USFDA for Apremilast Tablets."Cadila Healthcare Ltd - 532321 - Closure of Trading Window
Intimation for Closure of Trading WindowCadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
Disclosure of Form C submitted by Chief Financial Officer for sell of sharesCadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
Disclosure in prescribed Form 'C' under Regulation 7[2] of SEBI [Prohibition of Insider Trading] Regulations, 2015India to open COVID-19 vaccination for 12-18 years age group in October
Cadila Healthcare's ZyCoV-D, the only COVID-19 vaccine approved for children in India, will be available from next monthCadila Healthcare share price falls on sale of two brands
Purchaser is a part of the portfolio companies of PE firm True North and said the transaction is not a related party transaction.Cadila Healthcare Ltd - 532321 - Announcement Under Regulation 30
Zydus Healthcare Limited, a wholly owned subsidiary of the Company has entered into an agreement today i.e. September 20, 2021 with Integrace Private Limited ('Purchaser') to sell two brands viz. Mifegest and Cytolog.Zydus Cadila gets USFDA nod to market depression treatment drug in US
Drug firm Zydus Cadila on Saturday said it has received approval from the US health regulator to market Vortioxetine Tablets, used to treat depression, in the American market.Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release dated September 18, 2021 titled 'Zydus Cadila receives final approval from USFDA for Vortioxetine Tablets".Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement of Notice of Loss of Share Certificate of the Company